Table 2. Screening COVID-19 patients involved assessing SARS-CoV-2 variants, age, gender, and severity.
Screening process of COVID-19 patients (n = 210) into Asymptomatic (n = 113) and Symptomatic (n = 85) categories based on clinical parameters. the groups were segregated based on gender into females (n = 96) and males (n = 102), as well as based on age into young (age between 19 and 49 years old) individuals (n = 111) and old (age between 50 and 89 years old) individuals (n = 87). Blood and nasopharyngeal swabs were collected from all the subjects and a qRT-PCR assay was performed. Six novel nonsynonymous mutations (Δ69–70, Δ242–244, N501Y, E484K, L452R, and T478K) were used to identify the haplotypes unique to different SARS-CoV-2 variants of concern (Omicron (B.1.1.529 (BA.1)), Omicron (B.1.1.529 (BA.2)), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Epsilon (B.1.427/B.1.429)).
| Symptom | Gender | Age | |||||
|---|---|---|---|---|---|---|---|
| Variants of Concern | SYMP (%) | ASYMP (%) | Male (%) | Female (%) | Young (%) | Old (%) | Total Sample Size (%) |
| B.1.1.7 (Alpha) | 10 (45.4) | 12 (54.6) | 12 (54.5) | 10 (45.5) | 14 (63.6) | 8 (36.4) | 22 (11.1) |
| B.1.351(Beta) | 8 (47.1) | 9 (52.9) | 8 (47.1) | 9 (52.9) | 11 (64.7) | 6 (35.3) | 17 (8.6) |
| P.1. (Gamma) | 6 (31.5) | 13 (68.5) | 9 (47.3) | 10 (52.7) | 10 (52.7) | 9 (47.3) | 19 (9.6) |
| B.1.617.2 (Delta) | 18 (40.9) | 26 (59.1) | 24 (54.5) | 20 (45.5) | 24 (54.5) | 20 (45.5) | 44 (22.2) |
| B.1.427/B.1.429 (Epsilon) | 16 (51.6) | 15 (48.4) | 17 (54.8) | 14 (45.2) | 20 (64.5) | 11 (35.5) | 31 (15.7) |
| B.1.1.529 (BA.1) Omicron | 17 (48.5) | 18 (51.5) | 16 (45.7) | 19 (54.3) | 16 (45.7) | 19 (54.3) | 35 (17.7) |
| B.1.1.529 (BA.2) Omicron | 10 (33.3) | 20 (66.7) | 16 (53.3) | 14 (46.7) | 16 (53.3) | 14 (46.6) | 30 (15.1) |